3.77
3.57%
+0.13
Caribou Biosciences Inc stock is currently priced at $3.77, with a 24-hour trading volume of 1.81M.
It has seen a +3.57% increased in the last 24 hours and a -19.44% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $3.67 pivot point. If it approaches the $3.79 resistance level, significant changes may occur.
Previous Close:
$3.64
Open:
$3.77
24h Volume:
1.81M
Market Cap:
$340.50M
Revenue:
$34.48M
Net Income/Loss:
$-102.07M
P/E Ratio:
-2.0714
EPS:
-1.82
Net Cash Flow:
$-104.90M
1W Performance:
+1.62%
1M Performance:
-19.44%
6M Performance:
-9.81%
1Y Performance:
-12.93%
Caribou Biosciences Inc Stock (CRBU) Company Profile
Name
Caribou Biosciences Inc
Sector
Industry
Phone
510-982-6030
Address
2929 7th Street, Suite 105, Berkeley
Caribou Biosciences Inc Stock (CRBU) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-11-23 | Initiated | Truist | Buy |
Feb-18-22 | Initiated | RBC Capital Mkts | Outperform |
Dec-01-21 | Initiated | Oppenheimer | Outperform |
Nov-30-21 | Initiated | H.C. Wainwright | Buy |
Nov-15-21 | Upgrade | Citigroup | Neutral → Buy |
Aug-17-21 | Initiated | BofA Securities | Buy |
Aug-17-21 | Initiated | Citigroup | Neutral |
Aug-17-21 | Initiated | SVB Leerink | Outperform |
View All
Caribou Biosciences Inc Stock (CRBU) Latest News
Caribou Biosciences Announces Oral Presentation on In Vivo Cas12a chRDNA Genome Editing at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
GlobeNewswire Inc.
Kura Sushi Posts Upbeat Sales, Joins Caribou Biosciences, Krispy Kreme And Other Big Stocks Moving Higher In Friday's Pre-Market Session
Benzinga
Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus
GlobeNewswire Inc.
All You Need to Know About Caribou Biosciences, Inc. (CRBU) Rating Upgrade to Buy
Zacks Investment Research
Investor Sentiment Improves Following Inflation Data, Dow Jumps Over 200 Points
Benzinga
Gold Down Over 1%; ClearOne Shares Spike Higher
Benzinga
Caribou Biosciences Inc Stock (CRBU) Financials Data
Caribou Biosciences Inc (CRBU) Revenue 2024
CRBU reported a revenue (TTM) of $34.48 million for the quarter ending December 31, 2023, a +148.91% rise year-over-year.
Caribou Biosciences Inc (CRBU) Net Income 2024
CRBU net income (TTM) was -$102.07 million for the quarter ending December 31, 2023, a -2.66% decrease year-over-year.
Caribou Biosciences Inc (CRBU) Cash Flow 2024
CRBU recorded a free cash flow (TTM) of -$104.90 million for the quarter ending December 31, 2023, a -7.02% decrease year-over-year.
Caribou Biosciences Inc (CRBU) Earnings per Share 2024
CRBU earnings per share (TTM) was -$1.46 for the quarter ending December 31, 2023, a +10.98% growth year-over-year.
About Caribou Biosciences Inc
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. Caribou Biosciences has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.
Cap:
|
Volume (24h):